Home » Glenmark’s Abiraterone Acetate Tablets Approved
Glenmark’s Abiraterone Acetate Tablets Approved
The FDA approved Glenmark Pharmaceuticals’ abiraterone acetate 250 mg as a generic of Janssen’s prostate cancer drug Zytiga (abiraterone).
Janssen earned approximately $794 million from sales of the Zytiga 250 mg for the 12-month period ending August 2019.
The approval brings Glenmark’s portfolio to 162 products authorized for distribution in the U.S., with 46 ANDA’s pending approval, the company said.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May